Enhanced amphetamine-mediated dopamine release develops in PC12 cells after repeated amphetamine treatment

European Journal of Pharmacology

Volumn 451, Issue 1, 2002, Pages 27-35

  Kantor, Lana ^a   Park, Yang Hae ^a   Wang, Kevin K W ^a,b   Gnegy, Margaret E ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b PFIZER INC   (United States)

Author keywords

Dopamine uptake; Intermittent; Nerve growth factor; Nisoxetine; Norepinephrine transporter; Withdrawal time

Indexed keywords

AMPHETAMINE; DOPAMINE; NERVE GROWTH FACTOR; NORADRENALIN TRANSPORTER;

ANIMAL CELL; ARTICLE; CATECHOLAMINE NERVE CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINE UPTAKE; DRUG EFFECT; HUMAN; HUMAN CELL; NEUROANATOMY; NONHUMAN; PRIORITY JOURNAL; RAT; SYNAPSE;

AMPHETAMINE; ANIMALS; DOPAMINE; FLUOXETINE; NERVE GROWTH FACTOR; PC12 CELLS; RATS;

EID: 0037031538     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02190-8     Document Type: Article

References (48)

1. Apparsundaram S., Schroeter S., Giovanetti E., Blakely R.D. Acute regulation of norepinephrine transport: II. PKC-modulated surface expression of human norepinephrine transporter proteins. J. Pharmacol. Exp. Ther. 287:1998;744-751.
2. Bryan-Lluka L.J., Paczkowski F.A., Bonisch H. Effects of short- and long-term exposure to c-AMP and c-GMP on the noradrenaline transporter. Neuropharmacology. 40:2001;607-617.
3. Buck K.J., Amara S.G. Structural domains of catecholamine transporter chimeras involved in selective inhibition by antidepressants and psychomotor stimulants. Mol. Pharmacol. 48:1995;1030-1037.
4. Calabresi P., Maj R., Pisani A., Mercuri N.B., Bernardi G. Long-term synaptic depression in the striatum: physiological and pharmacological characterization. J. Neurosci. 12:1992;4224-4233.
5. Calabresi P., Pisani A., Centonze D., Bernardi G. Synaptic plasticity and physiological interactions between dopamine and glutamate in the striatum. Neurosci. Biobehav. Rev. 21:1997;519-523.
6. Cowell R.M., Kantor L., Hewlett G.H., Frey K.A., Gnegy M.E. Dopamine transporter antagonists block phorbol ester-induced dopamine release and dopamine transporter phosphorylation in striatal synaptosomes. Eur. J. Pharmacol. 389:2000;59-65.
7. Danek Burgess K.S., Justice J.B. Jr. Effects of serine mutations in transmembrane domain 7 of the human norepinephrine transporter on substrate binding and transport. J. Neurochem. 73:1999;656-664.
8. Di Chiara G. The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend. 38:1995;95-137.
9. Ellison G., Morris W. Opposed stages of continuous amphetamine administration: parallel alterations in motor stereotypies and in vivo spiroperidol accumulation. Eur. J. Pharmacol. 74:1981;207-214.
10. Engber T.M., Susel Z., Juncos J.L., Chase T.N. Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. Eur. J. Pharmacol. 168:1989;291-298.
11. Fischer J.F., Cho A.K. Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J. Pharmacol. Exp. Ther. 208:1979;203-209.
12. Flores C., Rodaros D., Stewart J. Long-lasting induction of astrocytic basic fibroblast growth factor by repeated injections of amphetamine: blockade by concurrent treatment with a glutamate antagonist. J. Neurosci. 18:1998;9547-9555.
13. - in transport. Naunyn-Schmiedeberg's Arch. Pharmacol. 333:1986;246-252.
14. Glenthoj B.Y. The brain dopaminergic system. Pharmacological, behavioural and electrophysiological studies. Dan. Med. Bull. 42:1995;1-21.
15. Greene L.A., Rein G. Release, storage and uptake of catecholamines by a clonal cell line of nerve growth factor (NGF) responsive pheochromocytoma cells. Brain Res. 129:1977;247-263.
16. Greene L.A., Tischler A.S. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc. Natl. Acad. Sci. U. S. A. 73:1976;2424-2428.
17. Gu H., Wall S.C., Rudnick G. Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J. Biol. Chem. 269:1994;7124-7130.
18. Iwata S., Hewlett G.H.K., Gnegy M.E. Amphetamine increases the phosphorylation of neuromodulin and synapsin I in rat striatal synaptosomes. Synapse. 26:1997;281-291.
19. Iwata S., Nomoto M., Kaseda S., Tanoue S., Shimosaka M., Fukuda T. TH protein and mRNA in nigrostriatal dopaminergic neurons are down-regulated by continuous but not intermittent apomorphine. Brain Res., Mol. Brain Res. 82:2000;133-136.
20. Jaber M., Cador M., Dumartin B., Normand E., Stinus L., Bloch B. Acute and chronic amphetamine treatments differently regulate neuropeptide messenger RNA levels and Fos immunoreactivity in rat striatal neurons. Neuroscience. 65:1995;1041-1050.
21. Kantor L., Gnegy M.E. Protein kinase C inhibitors block amphetamine-mediated dopamine release in rat striatal slices. J. Pharmacol. Exp. Ther. 284:1998;594-598.
22. 2+- and calmodulin-dependent phosphorylation and synaptic vesicles. J. Neurosci. 19:1999;3801-3808.
23. Kantor L., Hewlett G.H., Park Y.H., Richardson-Burns S.M., Mellon M.J., Gnegy M.E. Protein kinase C and intracellular calcium are required for amphetamine-mediated dopamine release via the norepinephrine transporter in undifferentiated PC12 cells. J. Pharmacol. Exp. Ther. 297:2001;1016-1024.
24. Kittner B., Brautigam M., Herken H. PC12 cells: a model system for studying drug effects on dopamine synthesis and release. Arch. Int. Pharmacodyn. Ther. 286:1987;181-194.
25. Kolta M.G., Shreve P., De Souza V., Uretsky N.J. Time course of the development of the enhanced behavioral and biochemical responses to amphetamine after pretreatment with amphetamine. Neuropharmacology. 24:1985;823-829.
26. Malenka R.C., Nicoll R.A. Long-term potentiation - a decade of progress? Science. 285:1999;1870-1874.
27. Morelli M., Fenu S., Garau L., Di Chiara G. Time and dose dependence of the 'priming' of the expression of dopamine receptor supersensitivity. Eur. J. Pharmacol. 162:1989;329-335.
28. Norman A.B., Lu S.Y., Klug J.M., Norgren R.B. Sensitization of c-fos expression in rat striatum following multiple challenges with D-amphetamine. Brain Res. 603:1993;125-128.
29. Paulson P.E., Robinson T.E. Amphetamine-induced time-dependent sensitization of dopamine neurotransmission in the dorsal and ventral striatum: a microdialysis study in behaving rats. Synapse. 19:1995;56-65.
30. Pierce R.C., Kalivas P.W. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res., Brains Res. Rev. 25:1997;192-216.
31. Post R.M. Intermittent versus continuous stimulation: effect of time interval on the development of sensitization or tolerance. Life Sci. 26:1980;1275-1282.
32. Robinson T.E. The neurobiology of amphetamine psychosis: evidence from studies with an animal model. Nakazawa T. Taniguchi Symposia on Brain Sciences. Biological Basis of Schizophrenic Disorders. vol. 14:1991;185-201 Japan Scientific Societies Press, Tokyo.
33. Robinson T.E. Persistent sensitizing effects of drugs on brain dopamine systems and behavior: implications for addiction and relapse. Barchas J., Korenman S. The Biological Basis of Substance Abuse. 1992;373-403 Oxford Univ. Press, New York.
34. Robinson T.E., Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brains Res. Rev. 11:1986;157-198.
35. Robinson T.E., Kolb B. Alterations in the morphology of dendrites and dendritic spines in the nucleus accumbens and prefrontal cortex following repeated treatment with amphetamine or cocaine. Eur. J. Neurosci. 11:1999;1598-1604.
36. Seiden L.S., Sabol K.E., Ricaurte G.A. Amphetamine: effects on catecholamine systems and behavior. Annu. Rev. Pharmacol. Toxicol. 33:1993;639-677.
37. Simpson J.N., Wang J.Q., McGinty J.F. Repeated amphetamine administration induces a prolonged augmentation of phosphorylated cyclase response element-binding protein and Fos-related antigen immunoreactivity in rat striatum. Neuroscience. 69:1995;441-457.
38. Sitte H.H., Hiptmair B., Zwach J., Pifl C., Singer E.A., Scholze P. Quantitative analysis of inward and outward transport rates in cells stably expressing the cloned human serotonin transporter: inconsistencies with the hypothesis of facilitated exchange diffusion. Mol. Pharmacol. 59:2001;1129-1137.
39. Strakowski S.M., Sax K.W., Setters M.J., Keck P.E. Jr. Enhanced response to repeated D-amphetamine challenge: evidence for behavioral sensitization in humans. Biol. Psychiatry. 40:1996;872-880.
40. Sulzer D., Chen T.-K., Lau Y.Y., Kristensen H., Rayport S., Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 15:1995;4102-4108.
41. Turgeon S.M., Pollack A.E., Fink J.S. Enhanced CREB phosphorylation and changes in c-Fos and FRA expression in striatum accompany amphetamine sensitization. Brain Res. 749:1997;120-126.
42. Vaughn D.M., Severson J.A., Woodward J.J., Randall P.K., Riffee W.H., Leslie S.W., Wilcox R.E. Behavioral sensitization following subchronic apomorphine treatment - Possible neurochemical basis. Brain Res. 526:1990;37-44.
43. Wall S.C., Gu H., Rudnick G. Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux. Mol. Pharmacol. 47:1995;544-550.
44. White F.J., Hu X.-T., Brooderson R.J. Repeated stimulation of dopamine D1 receptors enhances the effects of dopamine receptor agonists. Eur. J. Pharmacol. 191:1990;497-499.
45. Wolf M.E. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog. Neurobiol. 54:1998;679-720.
46. Wolf M.E., White F.J., Nassar R., Brooderson R.J., Khansa M.R. Differential development of autoreceptor subsensitivity and enhanced dopamine release during amphetamine sensitization. J. Pharmacol. Exp. Ther. 264:1993;249-255.
47. Zhu J., Hexum T.D. Characterization of cocaine-sensitive dopamine uptake in PC12 cells. Neurochem. Int. 21:1992;521-526.
48. Zhu M.Y., Ordway G.A. Down-regulation of norepinephrine transporters on PC12 cells by transporter inhibitors. J. Neurochem. 68:1997;134-141.